About: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$1.57 (-5.99%)
CU6 ASX Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd share price
Atividade de preço de CU6
Último preço
$ 1,570
Variação (24h)
-0,10 AUD (5,99%)
Volume
2.98M
Volume (média 4 sem.)
-
Abertura
$ 1,65
Variação do dia
$ 1,55 - $ 1,67
Fechamento anterior
$ 1,67
Último negócio
30 Oct, 5:32 am GMT+0
Atrasado
30 Oct, 5:32 am GMT+0
CU6 price performance
Atrasado
30 Oct, 5:32 am GMT+0
quote.marketSignals